No Prescription |
 |
 | ||
|
CHRONAL Antabuse |
|
| ||
No Prescription » Prescription Drugs 4 » CHRONAL Antabuse This medication is used along with counseling and support to treat alcoholism. Disulfiram works by blocking the processing of alcohol in the body. This causes you to have a bad reaction when you drink alcohol.How to use Disulfiram OralTake this medication by mouth with or without food usually once daily in the morning or as directed by your doctor. If this medication causes drowsiness take it at bedtime.Dosage is based on your medical condition and response to therapy. The maximum recommended daily dose is 500 milligrams.Use this medication regularly to get the most benefit from it. To help you remember take it at the same time each day.Disulfiram Oral is used to treat the following:Habit of Drinking Too Much Alcohol Buy CHRONAL Antabuse and other Prescription Drugs 4 products online at Medstore. Buy Online at Medstore - Click Here!
About CHRONAL Antabuse: Product Type: Prescription Drugs 4 CHRONAL ( Antabuse Generic Disulfiram ) CHRONAL (Antabuse Generic Disulfiram) Antabuse Generic Disulfiram 500mg 100 Tablets 4 x 100 Tablets 2 x 100 Tablets Antabuse Generic Disulfiram CHRONAL
View more Prescription Drugs 4 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
